Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Amortizatization of Intangibles (2016 - 2025)

Historic Amortizatization of Intangibles for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $1.3 million.

  • Spyre Therapeutics' Amortizatization of Intangibles fell 5501.5% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.4 million, marking a year-over-year decrease of 2120.48%. This contributed to the annual value of $11.4 million for FY2024, which is 39197.58% up from last year.
  • Per Spyre Therapeutics' latest filing, its Amortizatization of Intangibles stood at $1.3 million for Q3 2025, which was down 5501.5% from $2.0 million recorded in Q2 2025.
  • Spyre Therapeutics' Amortizatization of Intangibles' 5-year high stood at $3.6 million during Q2 2024, with a 5-year trough of -$181000.0 in Q1 2021.
  • Moreover, its 5-year median value for Amortizatization of Intangibles was $164000.0 (2023), whereas its average is $1.0 million.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first crashed by 170000.0% in 2021, then soared by 625892.86% in 2024.
  • Spyre Therapeutics' Amortizatization of Intangibles (Quarter) stood at -$58000.0 in 2021, then skyrocketed by 281.03% to $105000.0 in 2022, then surged by 1524.76% to $1.7 million in 2023, then skyrocketed by 41.79% to $2.4 million in 2024, then crashed by 44.19% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $2.0 million for Q2 2025, and $2.6 million during Q1 2025.